RCKT News and Press, Rocket Pharmaceuticals Inc.

2024-06-28 12:08:19 ET Summary Rocket Pharmaceuticals stock dropped pre-market after management reported receiving a Complete Response Letter from the FDA in relation to Kresladi, indicated for severe leukocyte adhesion deficiency-I. The rejection was based on Chemistry Manufactur...

2024-06-28 08:21:35 ET More on Rocket Pharmaceuticals Rocket Pharmaceuticals: Cautiously Optimistic (Rating Upgrade) Rocket Pharmaceuticals: Multiple Regulatory Submissions Make It A Must Watch Cantor picks 14 undervalued biotech stocks worth a second look Ro...

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet needs, today announced a regulatory update for KRESLADI™ (marnetegragene autotemcel; marne-cel), a le...

2024-06-21 15:00:42 ET More on the markets SPY: The Upside Is Likely Capped SPY: Rating Downgrade Due To Overvaluation Perfect Time For November Election Protection UBS says the current market conditions and the late 1990s have many differences Wolfe ...

2024-06-02 14:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the European Commission (EC), based on a positive opinion issued by the Committ...

2024-05-12 11:00:00 ET More on Acadia Pharma, BridgeBio Pharma, etc. ACADIA Pharmaceuticals Inc. (ACAD) Q1 2024 Earnings Call Transcript ACADIA Pharmaceuticals Inc. 2024 Q1 - Results - Earnings Call Presentation Rocket Pharmaceuticals: Cautiously Optimistic (Rating U...

Long-term KRESLADI TM follow-up data demonstrate survival of 100% in the absence of allogeneic hematopoietic stem cell transplantation (HSCT) from 18 to 45 months with a well-tolerated safety profile in all nine patients with severe LAD-I Previously disclosed results from the global R...

2024-05-06 16:42:31 ET More on Rocket Pharmaceuticals Rocket Pharmaceuticals: Cautiously Optimistic (Rating Upgrade) Rocket Pharmaceuticals: Multiple Regulatory Submissions Make It A Must Watch Rocket Pharmaceuticals' Promising Path In Gene Therapy Rocket Pha...

Advanced RP-L102 for Fanconi Anemia towards regulatory reviews; EMA accepted MAA for review and BLA submission anticipated in the first half of 2024 Continued preparations to launch LV portfolio beginning with KRESLADI™ (marnetegragene autotemcel) for severe LAD-I; PDUFA date of Ju...